SEC Form 4 · accession 0001771814-26-000005
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jeffrey Bluestone
Director
Period of report
Aug 20, 2026
Accepted (ET)
Aug 21, 2026 · 7:22 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 20, 2026 | M | 1,165 | $67.45 | A | 11,231 | D | |
| Common StockF2 | Aug 20, 2026 | S | 1,165 | $143.7543 | D | 10,066 | D | |
| Common Stock | Aug 20, 2026 | M | 1,816 | $67.45 | A | 11,882 | D | |
| Common StockF3 | Aug 20, 2026 | S | 1,816 | $144.9248 | D | 10,066 | D | |
| Common Stock | Aug 20, 2026 | M | 1,658 | $67.45 | A | 11,724 | D | |
| Common StockF4 | Aug 20, 2026 | S | 1,658 | $145.7286 | D | 10,066 | D | |
| Common Stock | Aug 20, 2026 | M | 26 | $67.45 | A | 10,092 | D | |
| Common Stock | Aug 20, 2026 | S | 26 | $146.36 | D | 10,066 | D | |
| Common Stock | Aug 20, 2026 | M | 335 | $61.35 | A | 10,401 | D | |
| Common Stock | Aug 20, 2026 | S | 335 | $146.26 | D | 10,066 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-qualified Stock Option (Right to Buy)F5 | $67.45 | Aug 20, 2026 | M | 4,665 | D | — | May 12, 2031 | Common Stock | 4,665 | 0 | D |
| Non-qualified Stock Option (Right to Buy)F6 | $61.35 | Aug 20, 2026 | M | 335 | D | — | May 5, 2032 | Common Stock | 335 | 11,395 | D |
Explanation of responses
- F1The transaction reported in this Form 4 is made pursuant to a Rule 10b5-1 trading plan adopted on May 20, 2026.
- F2Sale prices for the transactions reported range from $143.31 to $144.16. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F3Sale prices for the transactions reported range from $144.32 to $145.31. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F4Sale prices for the transactions reported range from $145.34 to $146.23. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer, or its shareowners upon request.
- F525% of the shares subject to the option vested on each three-month anniversary from May 12, 2021 such that 100% of the shares subject to the option are fully vested.
- F6100% of the shares subject to the stock option vested immediately upon the grant date of May 5, 2022.